Loading...
Solasia Pharma K.K.
4597.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥45.00
¥0.00(0.00%)
Solasia Pharma K.K. (4597.T) Financial Performance & Income Statement Overview
Review Solasia Pharma K.K.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-48.78%
↓ 48.78%
Operating Income Growth
-71.29%
↓ 71.29%
Net Income Growth
-74.55%
↓ 74.55%
Operating Cash Flow Growth
-187.74%
↓ 187.74%
Operating Margin
-589.36%
↓ 589.36%
Gross Margin
55.02%
↑ 55.02%
Net Profit Margin
-584.19%
↓ 584.19%
ROE
-124.30%
↓ 124.30%
ROIC
-223.64%
↓ 223.64%
Solasia Pharma K.K. (4597.T) Income Statement & Financial Overview
Review Solasia Pharma K.K.'s (4597.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $235.00M | $9.00M | $60.00M | $11.00M |
| Cost of Revenue | $55.00M | $7.00M | $92.00M | $104.00M |
| Gross Profit | $180.00M | $2.00M | -$32.00M | -$93.00M |
| Gross Profit Ratio | $0.77 | $0.22 | -$0.53 | -$8.45 |
| R&D Expenses | $255.00M | $94.00M | $147.00M | $76.00M |
| SG&A Expenses | $1.14B | $190.00M | $158.00M | $139.00M |
| Operating Expenses | $1.24B | $283.00M | $271.00M | $215.00M |
| Total Costs & Expenses | $1.29B | $290.00M | $363.00M | $319.00M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $3.00M | $10.00M |
| Depreciation & Amortization | $9.25M | $142.00M | $34.00M | $93.00M |
| EBITDA | -$1.05B | -$140.00M | -$269.00M | -$215.00M |
| EBITDA Ratio | -$4.46 | -$15.56 | -$4.48 | -$19.55 |
| Operating Income | -$1.06B | -$281.00M | -$303.00M | -$308.00M |
| Operating Income Ratio | -$4.51 | -$31.22 | -$5.05 | -$28.00 |
| Other Income/Expenses (Net) | -$9.00M | $16.00M | -$6.00M | -$10.00M |
| Income Before Tax | -$1.07B | -$265.00M | -$309.00M | -$318.00M |
| Income Before Tax Ratio | -$4.54 | -$29.44 | -$5.15 | -$28.91 |
| Income Tax Expense | $2.00M | $5.00M | -$8.00M | -$8.00M |
| Net Income | -$1.07B | -$260.00M | -$300.00M | -$310.00M |
| Net Income Ratio | -$4.55 | -$28.89 | -$5.00 | -$28.18 |
| EPS | -$4.91 | -$1.23 | -$1.57 | -$1.78 |
| Diluted EPS | -$4.91 | -$1.23 | -$1.57 | -$1.78 |
| Weighted Avg Shares Outstanding | $217.95M | $211.76M | $191.08M | $174.04M |
| Weighted Avg Shares Outstanding (Diluted) | $218.03M | $211.76M | $191.08M | $174.04M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan